Evommune (EVMN) Capital Expenditures (2025 - 2026)

Evommune (EVMN) reported Capital Expenditures of $83000.0 for Q1 2026, up 186.46% quarter-over-quarter from -$96000.0 in Q4 2025.

Evommune (EVMN) Capital Expenditures (2025 - 2026) Analysis & Trends

Evommune (EVMN) has 2 years of Capital Expenditures data on file, last reported at $83000.0 in Q1 2026.

Capital Expenditures for Q1 2026 came in at $83000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$13000.0 (changed N/A YoY), and the FY2025 annual result was $35000.0, down 60.23% from the prior year.
Capital Expenditures improved to $83000.0 in Q1 2026 per EVMN's latest filing, from -$96000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $83000.0 in Q1 2026 and troughed at -$96000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	133.40 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-63,220.27
10	Evommune	695.29 Mn	483.82 Mn	-	83,000.00

Download Data